VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'
Leipzig, (PresseBox) - VITA 34 International AG (ISIN DE000A0BL849), the parent company of the leading private umbilical cord blood bank in the German-speaking countries VITA 34, received IND approval of its autologous Cord Blood for a clinical study in children with Type 1 Diabetes. The study will be performed by the Diabetes Research Institute of the Klinik und Poliklinik für Kinder- und Jugendmedizin of the Technical University Munich. A corresponding approval was granted by The Paul-Ehrlich-Institute, a high federal agency in Germany. The aim of the study is to investigate the safety and potential benefit of transfusing autologous Cord Blood in children who have newly manifested Type 1 Diabetes. The study is designed to last 24 months and will be controlled by a reference group. The risk of Type 1 Diabetes in Germany is about 1 in 600 by the age of fourteen. A similar pilot study in the USA shows promising results with regard to the disturbed immune balance, insulin requirements, and the quality of metabolic control.